Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RAYOS | Horizon Pharmaceutical | N-202020 RX | 2012-07-26 | 3 products, RLD, RS |
Code | Description |
---|---|
G2112 | Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months |
G2113 | Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity |
G9468 | Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills |
G9470 | Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills |
J7512 | Prednisone, immediate release or delayed release, oral, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 60 | 171 | 61 | 7 | 11 | 275 |
Lymphoma | D008223 | — | C85.9 | 23 | 86 | 42 | 1 | 11 | 151 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 34 | 74 | 40 | 4 | 4 | 136 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 21 | 48 | 27 | 8 | 12 | 101 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 22 | 43 | 17 | 2 | 2 | 73 |
Multiple myeloma | D009101 | — | C90.0 | 14 | 37 | 27 | 3 | 3 | 71 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 17 | 31 | 12 | 2 | 4 | 57 |
Kidney transplantation | D016030 | — | — | 5 | 14 | 5 | 21 | 2 | 44 |
T-cell lymphoma peripheral | D016411 | — | — | 12 | 25 | 7 | 2 | 1 | 42 |
Asthma | D001249 | EFO_0000270 | J45 | 4 | 5 | 12 | 11 | 11 | 41 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 7 | 28 | 18 | — | 7 | 53 |
Hodgkin disease | D006689 | — | C81 | 6 | 27 | 14 | — | 1 | 41 |
Neoplasms | D009369 | — | C80 | 13 | 10 | 2 | — | — | 19 |
Adenocarcinoma | D000230 | — | — | 1 | 16 | 1 | — | — | 18 |
Plasma cell neoplasms | D054219 | — | — | 4 | 6 | 5 | — | — | 14 |
T-cell lymphoma | D016399 | — | — | 4 | 3 | 3 | — | 2 | 12 |
Covid-19 | D000086382 | — | U07.1 | — | 4 | 6 | — | 3 | 11 |
Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | 4 | 4 | — | 3 | 11 |
Philadelphia chromosome | D010677 | — | — | 2 | 8 | 1 | — | — | 10 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 5 | 1 | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Burkitt lymphoma | D002051 | — | C83.7 | 10 | 9 | — | — | — | 16 |
Healthy volunteers/patients | — | — | — | 11 | 1 | — | — | 1 | 13 |
Myelodysplastic syndromes | D009190 | — | D46 | 5 | 9 | — | — | — | 12 |
Non-small-cell lung carcinoma | D002289 | — | — | 5 | 4 | — | — | — | 7 |
Aids-related lymphoma | D016483 | EFO_1001365 | — | 1 | 5 | — | — | — | 6 |
Myeloproliferative disorders | D009196 | — | D47.1 | 2 | 4 | — | — | — | 6 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 1 | 5 | — | — | — | 5 |
Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 4 | — | — | 1 | 5 |
Plasmablastic lymphoma | D000069293 | — | C83.3 | 4 | 3 | — | — | — | 5 |
Proteinuria | D011507 | HP_0000093 | R80 | — | 2 | — | — | 3 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pregnancy rate | D018873 | — | — | 1 | — | — | — | 4 | 5 |
Tinnitus | D014012 | HP_0000360 | H93.1 | 1 | — | — | — | 2 | 3 |
Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
Syndrome | D013577 | — | — | 1 | — | — | — | 1 | 2 |
Allergic rhinitis | D065631 | — | J30.9 | 1 | — | — | — | 1 | 2 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | 1 | 2 |
Drug hypersensitivity syndrome | D063926 | EFO_1002004 | D72.12 | 1 | — | — | — | 1 | 2 |
Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | — | 1 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pneumocystis | D011010 | — | — | — | — | — | — | 2 | 2 |
Allergic bronchopulmonary aspergillosis | D001229 | EFO_0007140 | B44.81 | — | — | — | — | 2 | 2 |
Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | — | 2 | 2 |
Undifferentiated connective tissue diseases | D000074079 | — | — | — | — | — | — | 1 | 1 |
Granulomatous mastitis | D058890 | — | N61.2 | — | — | — | — | 1 | 1 |
Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
Cytokine release syndrome | D000080424 | — | D89.83 | — | — | — | — | 1 | 1 |
Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
Squamous intraepithelial lesions | D000081483 | — | — | — | — | — | — | 1 | 1 |
Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 1 | 1 |
Drug common name | Prednisone |
INN | prednisone |
Description | Prednisone is a synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. It has a role as a prodrug, an anti-inflammatory drug, an antineoplastic agent, an immunosuppressive agent and an adrenergic agent. It is a 20-oxo steroid, an 11-oxo steroid, a 21-hydroxy steroid, a 17alpha-hydroxy steroid, a glucocorticoid, a 3-oxo-Delta(1),Delta(4)-steroid, a primary alpha-hydroxy ketone, a tertiary alpha-hydroxy ketone and a C21-steroid. |
Classification | Small molecule |
Drug class | prednisone and prednisolone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO |
PDB | — |
CAS-ID | 53-03-2 |
RxCUI | — |
ChEMBL ID | CHEMBL635 |
ChEBI ID | 8382 |
PubChem CID | 5865 |
DrugBank | DB00635 |
UNII ID | VB0R961HZT (ChemIDplus, GSRS) |